Applications for NY-ESO-1 Immunotherapies
The NY-ESO-1 (New York Esophageal Squamous Cell Carcinoma 1) antigen is restricted to germ and placental cells, with re-expression in tumor cells. NY-ESO-1 expression has been associated with many cancer types, including:
- bladder cancer
- breast cancer
- esophageal cancer
- head and neck cancer
- hepatocellular carcinoma
- metastatic melanoma
- non-small cell lung cancer
- ovarian cancer
- prostate cancer
- synovial sarcoma
NY-ESO-1 is one of the most immunogenic antigens of the cancer-testis antigen (CTA) family, which are known for their ability to induce a spontaneous immune response. NY-ESO-1 has been shown to induce both humoral and cellular immune responses.
As researchers continue to search for tumor-specific antigens for the development of immune-based modalities, NY-ESO-1 is considered to be an excellent candidate for immunotherapies. Its limited expression in normal cells, wide-ranging expression in tumors, and limited off-target toxicities make it a promising antigen.
There are dozens of clinical trials exploring the use of NY-ESO-1 in immune-based interventions. The usefulness of NY-ESO-1 as a biomarker is unclear.
About Our Anti-NY-ESO-1 T Cells
Our T cells specific for the tumor-associated antigen NY-ESO-1 recognize a peptide from NY-ESO-1 bound to HLA-A*02:01 with a sequence of SLLMWITQC from residues 157–165.
The donor is a healthy, Caucasian female with A negative blood type.
We have 80 vials available in this batch, but they may go quickly. Check the product listing for updated inventory and further details.
Let’s Get Started!
With so many applications, you’re sure to have a use for these versatile T cells in your lab. If you have any questions about getting started with NY-ESO-1-specific T cells, ask an Astarte Scientist.